Colloidal systems for the delivery of cyclosporin A to the anterior segment of the eye;Systèmes colloïdaux pour la délivrance de la ciclosporine A dans le segment antérieur de l'œil

Annales Pharmaceutiques Francaises

Volumn 69, Issue 2, 2011, Pages 116-123

  Di Tommaso, C ^a   Behar Cohen, F ^b,c   Gurny, R ^a   Moller M ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Bioavailability enhancement; Colloidal systems; Cyclosporin A; Drug delivery; Ophthalmics; Polymeric micelles

Indexed keywords

CYCLOCAT; CYCLOKAT; CYCLOSPORIN A; ENDURA; LIPID EMULSION; NANOPARTICLE; UNCLASSIFIED DRUG;

ANTERIOR EYE SEGMENT; ARTICLE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SYNTHESIS; DRY EYE; HUMAN; HYPERTENSION; KIDNEY DISEASE; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTERIOR EYE SEGMENT; CHEMISTRY, PHARMACEUTICAL; COLLOIDS; CYCLOSPORINE; DRUG DELIVERY SYSTEMS; EMULSIONS; HUMANS; MICELLES; NANOPARTICLES; OPHTHALMIC SOLUTIONS; POLYESTERS; POLYETHYLENE GLYCOLS;

EID: 79953062297     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2011.01.001     Document Type: Article

References (51)

1. Kulkarni P. Review: uveitis and immunosuppressive drugs. J Ocul Pharmacol Ther 2001, 17:181-187.
2. Italia J.I., Bhardwaj V., Ravi Kumar M.N.V. Disease, destination, dose and delivery aspects of ciclospor: the state of the art. Drug Discov Today 2006, 11:846-854.
3. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliver Rev 2006, 58:1131-1135.
4. Behar-Cohen F. Systèmes de deliverance des médicaments pour le segment antérieur bases fondamentales et applications cliniques. J Fr Ophthalmol 2002, 25:537-544.
5. Lang J.C. Ocular drug delivery conventional ocular formulations. Adv Drug Deliver Rev 1995, 16:39-43.
6. Furrer P, Delie F, Plazonnet B. Ophthalmic drug delivery. In: Rathbone MJ, editor. Drugs and the pharmaceutical sciences, modified release drug delivery technology, part II: ocular technologies. 2008. p. 59-84.
7. Furrer P., Plazonnet B., Mayer J.M., Gurny R. Application of in vivo confocal microscopy to the objective evaluation of ocular irritation induced by surfactants. Int J Pharm 2000, 207:89-98.
8. Liu H., Wang W., Li S. Advanced delivery of Cyclosporin A: present state and perspective. Expert Opin Drug Deliv 2007, 4:349-358.
9. Donnefeld E., Pflugfelder S.C. Topical ophthalmic Cyclosporine: pharmacology and clinical uses. Surv Ophthalmol 2009, 54:321-338.
10. Pflugfelder S.C., Whilhelmus K.R., Osato A.S., Matoba A.Y., Font R.L. The autoimmune nature of aqueous tear deficiency. J Ophthalmol 1986, 93:1513-1517.
11. Wieczorek R., Jakobiec F.A., Sacks E.H., Knowles D.M. The immunoarchitectures of the normal lachrymal gland. Relevancy for understanding pathologic conditions. Ophthalmology 1988, 95:100-109.
12. Calonge M. The treatment of dry eye. Surv Ophthalmol 2001, 45:227-239.
13. MaCabe E., Narayanan S. Advancements in anti-inflammatory therapy for dry eye syndrome. Optometry 2009, 80:555-566.
14. Mondon K, Zeisser-Labouèbe M, Gurny R, Moller M. Novel Cyclosporin A formulations using MPEG-hexyl substituted polylactide micelles: a suitability study. Eur J Pharm Biopharm 2010; doi:10.1016/j.ejpb.2010.09.012.
15. El Tayar N., Mark J.A.E., Vallat P., Brunne R.M., Testa B., van Gunsterent W.F. Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations. J Med Chem 1993, 36:3757-3764.
16. Lallemand F., Felt-Baeyens O., Besseghir K., Behar-Cohen F., Gurny R. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm 2003, 56:307-318.
17. International Union of Pure and Applied Chemistry. Manual of colloid science. London: Butterworth; 1972.
18. Talmivanan S., Benita S. The potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur J Pharm Biopharm 2004, 58:357-358.
19. Ding S, Olejnik O, Reis B. Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers. Pat. No. 5981607. 1999.
20. Acheampong A.A, Shackteleton M., Tang-Liu D.D.S., Ding S., Stern M.E., Decker R. Distribution of Cyclosporin A after topical administration to albino rabbits and beagle dogs. Curr Eye Res 1999, 18:91-103.
21. Stevenson D., Tauber J., Reis B.R. Efficacy and safety of Cyclosporin A ophthalmic emulsion in the treatment of moderate to severe dry eye disease. Ophthalmology 2000, 107:967-974.
22. Sall K., Stevenson O.D., Mundorf T.K., Reis B.L. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000, 107:631-639.
23. Rao S.N. Topical cyclosporine 0.05% for the prevention of dry eye disease progression. J Ocul Pharmacol Ther 2010, 26:157-164.
24. Maissa C., Guillon M., Simmons P., Vehige J. Effect of castor oil emulsion eyedrops on tear film composition and stability. Cont Lens Anterior Eye 2010, 33:76-82.
25. Rabinovich-Guilatt L., Couvreur P., Lambert G., Dubernet C. Cationic vectors in ocular drug delivery. J Drug Target 2004, 12:623-633.
26. Gutiérrez J.M., Gonzalez C., Maestro A., Solè I., Pey C.M., Nolla J. Nano-emulsions: new applications and optimization of their preparation. Curr Opin Colloid In 2008, 13:245-251.
27. Solans C., Izquierdo P., Nolla J., Azemar N., Garcia-Celma M.J. Nano-emulsions. Curr Opin Colloid In 2005, 10:102-110.
28. Anton N., Gayet P., Benoit J.P., Saulnier P. Nano-emulsions and nanocapsules by the PIT method: an investigation on the role of the temperature cycling on the emulsion phase inversion. Int J Pharm 2007, 344:44-52.
29. Ugelstad J., El-Aaser M.S., Vanderhoff J.W. Emulsion polymerization. Initiation of polymerization in monomer droplets. J Polym Sci Pol Lett 1973, 11:503-513.
30. Gan L., Gan Y., Zhu C., Zhankg X., Zhu Y. Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic Cyclosporine A: in vitro and in vivo results. Int J Pharm 2009, 365:143-149.
31. Bague S, Philips B, Rabinovich-Guillatt L, Lambert G, Garrigue JS. Ophthalmic oil-in-water type emulsion with stable positive zeta potential. European Patent EP1809237. 2005.
32. Klang S., Abdulrazik M., Benita S. Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Pharm Dev Technol 2000, 5:521-532.
33. Abdulrazik M., Tamilvanan S., Khoury K., Benita S. Ocular delivery of Cyclosporin A. II. Effect of submicron emulsion's surface charge on ocular distribution of topical cyclosporin A. STP Pharm Sci 2001, 11:427-432.
34. Sahoo S.K., Dilnawaz F., Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today 2008, 13:144-151.
35. Yenice I., Mocan M.C., Palaska E., lie Bochot A., Bilensoy E., Vural I., et al. Hyaluronic acid coated poly-3-caprolactone nanospheres deliver high concentrations of cyclosporin A into the cornea. Exp Eye Res 2008, 87:162-167.
36. Gocke E.H., Sandri G., Bonferoni M.C., Rossi S., Ferrari F., Guneri T., et al. Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm 2008, 364:76-86.
37. Basaran E., Demirel M., Sirmagul B., Yazan Y. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul 2010, 27:37-47.
38. Shen J., Wang Y., Ping Q., Xiao Y., Huang X. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J Control Release 2009, 137:217-223.
39. De la Fuente M., Ravina M., Paolicelli P., Sanchez A., Seijo B., Alonso M.J. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev 2010, 62:100-117.
40. De Salamanca A.E., Diebold Y., Calonge M., Garcia-Vazquez C., Callejo S., Vila A., et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. IOVS 2006, 47:1416-1425.
41. Felt O., Furrer P., Mayer J.M., Plazonnet B., Buri P., Gurny R. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. Int J Pharm 1999, 180:185-193.
42. De Campos A.M., Sanchez A., Alonso M.J. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm 2001, 224:159-168.
43. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007, 24:1-16.
44. Nishiyama N., Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 2006, 112:630-648.
45. Kataoka K., Harada A., Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2001, 47:113-131.
46. Kuwano M., Ibuki H., Morikawa N., Ota A., Kawashima Y., Cyclosporine A formulation affect its ocular distribution in rabbits. Pharm Res 2002, 19:108-111.
47. Trimaille T., Gurny R., Möller M. Synthesis and ring-opening polymerization of new monoalkyl-substituted lactides. J Polym Sci A Polym Chem 2004, 42:4379-4391.
48. Trimaille T., Gurny R., Möller M. Synthesis and properties of novel poly(hexyl-substituted lactides) for pharmaceutical applications. Chimia 2005, 59:348-352.
49. Nottelet B., Di Tommaso C., Mondon K., Gurny R., Möller M. Fully biodegradable polymeric micelles based on hydrophobic- and hydrophilic-functionalized poly(lactide) block copolymers. J Polym Chem A Polym Chem 2010, 48:3244-3254.
50. Trimaille T., Mondon K., Gurny R., Möller M. Novel polymeric micelles for hydrophobic drug delivery based on biodegradable poly(hexyl-substituted lactides). Int J Pharm 2006, 319:147-154.
51. Di Tommaso C., Como C., Gurny R., Moller M. Investigations on the lyophilisation of MPEG-hexPLA micelles based pharmaceutical formulations. Eur J Pharm Sci 2010, 16:38-47.